Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Neurobiology (June) | 2018

View Archived Issues

CME Post-Test - Neurobiology, TCPR, June 2018

June 1, 2018

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits. Read More

A Look at the Latest Antidepressant Meta-Analysis

June 1, 2018

Adam Strassberg, MD

You may have read about the meta-analysis published in Lancet earlier this year on the efficacy evidence for all antidepressants (Cipriani A et al, Lancet 2018;391(10128):1357–1366). It’s a complicated paper, and in this article, we’ll take a closer look at it and give you our take on the bottom line. Read More

Neurobiology Concepts for Psychiatrists

June 1, 2018

David M. Kaufman, MD

The most common cause of parkinsonism is Parkinson disease, but parkinsonism also can occur from the use of any medication that blocks the D2 (dopamine type 2) receptor. Those include antipsychotics but can also include non-psychiatric medicines, particularly metoclopramide (Reglan), an anti-nausea medicine. Read More

The Neuroscience Behind Addictions and SSRIs

June 1, 2018

Edmund S. Higgins, MD.

If we think of the molecules (the endorphins or the opioids) as “keys” and the receptors on the neurons as “locks,” then one needs the right key in the lock to get the reward—to turn on the good feelings. Read More

Dose Maintenance, Reduction With Antipsychotics

June 1, 2018

Adam Strassberg, MD.

Once patients with schizophrenia are stabilized on an antipsychotic in the acute phase of their treatment, guidelines are unclear on how to continue dosing. Some guidelines recommend lowering the dose, others recommend maintaining the dose, and others give no firm recommendations whatsoever. Read More

Lithium Favored in Treatment Effectiveness Study

June 1, 2018

Adam Strassberg, MD.

A new study from Finland shows that lithium may be more effective than other treatments in reducing the risk of psychiatric rehospitalization in patients with bipolar disorder. Read More